Literature DB >> 21221558

Usefulness of thallium-201 SPECT in the evaluation of tumor natures in intracranial meningiomas.

Tetsuji Takeda1, Takahiro Nakano, Kenichiroh Asano, Norihito Shimamura, Hiroki Ohkuma.   

Abstract

INTRODUCTION: Although intracranial meningiomas are regarded as benign tumors, some of them behave clinically as malignant tumors. Past reports suggest that MIB 1 and vascular endothelial growth factor (VEGF) in postoperative tumor specimens correlate with the aggressive nature of tumors, but preoperative prediction of such a nature is more useful for therapeutic planning for the tumor. The purpose of this study was to assess the usefulness of preoperative thallium-201 chloride single-photon emission computed tomography (Tl SPECT) to evaluate biological behavior in intracranial meningiomas.
METHODS: Tl SPECT was performed on 39 patients with intracranial meningioma and Tl uptake indices were calculated. The difference in the Tl uptake index between atypical meningiomas and other pathological types of meningioma was evaluated. Moreover, correlation of Tl uptake indices with the MIB1 labeling index was estimated. Tl uptake indices were also compared between VEGF strongly positive and weakly positive meningiomas.
RESULTS: The delayed index of atypical meningioma was significantly higher than that of the other pathological types (p = 0.036). Significant correlation was found between the Tl uptake index in the delayed image and MIB1 labeling index (p < 0.0001, R (2) = 0.36). Moreover, VEGF strongly positive meningiomas exhibited a significantly higher Tl uptake index compared to VEGF weakly positive meningiomas in both the early image and the delayed image (p = 0.029, 0.023, respectively).
CONCLUSIONS: Tl uptake index may be a possible preoperative surrogate marker of MIB1 and VEGF that is useful in detecting aggressive natures in intracranial meningiomas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21221558     DOI: 10.1007/s00234-010-0822-2

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  26 in total

1.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  D SIMPSON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1957-02       Impact factor: 10.154

2.  Use of 201Thallium brain SPECT, image registration, and semi-quantitative analysis in the follow-up of brain tumors.

Authors:  R Rubinstein; H Karger; U Pietrzyk; T Siegal; J M Gomori; R Chisin
Journal:  Eur J Radiol       Date:  1996-02       Impact factor: 3.528

3.  Meningiomas: role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema.

Authors:  J Provias; K Claffey; L delAguila; N Lau; M Feldkamp; A Guha
Journal:  Neurosurgery       Date:  1997-05       Impact factor: 4.654

4.  Usefulness of thallium-201 single photon emission computed tomography to quantify the malignancy grade of brain tumors.

Authors:  K Igase; Y Oka; S Ohta; Y Murakami; Y Kumon; S Sakaki
Journal:  Neurol Med Chir (Tokyo)       Date:  1996-07       Impact factor: 1.742

5.  Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy.

Authors:  K Lamszus; U Lengler; N O Schmidt; D Stavrou; S Ergün; M Westphal
Journal:  Neurosurgery       Date:  2000-04       Impact factor: 4.654

6.  Different thallium-201 single-photon emission tomographic patterns in benign and aggressive meningiomas.

Authors:  E Tedeschi; A Soricelli; A Brunetti; M Romano; A Bucciero; G Iaconetta; A Alfieri; A Postiglione; M Salvatore
Journal:  Eur J Nucl Med       Date:  1996-11

7.  Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.

Authors:  D Kahn; K A Follett; D L Bushnell; M A Nathan; J G Piper; M Madsen; P T Kirchner
Journal:  AJR Am J Roentgenol       Date:  1994-12       Impact factor: 3.959

8.  Thallium-201 SPECT for predicting histological types of meningiomas.

Authors:  S Jinnouchi; H Hoshi; T Ohnishi; S Futami; S Nagamachi; K Watanabe; T Ueda; S Wakisaka
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

9.  The recurrence of intracranial meningiomas after surgical treatment.

Authors:  A B Adegbite; M I Khan; K W Paine; L K Tan
Journal:  J Neurosurg       Date:  1983-01       Impact factor: 5.115

10.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

View more
  4 in total

1.  SPECT and PET imaging of meningiomas.

Authors:  Varvara Valotassiou; Anastasia Leondi; George Angelidis; Dimitrios Psimadas; Panagiotis Georgoulias
Journal:  ScientificWorldJournal       Date:  2012-05-01

2.  Microcystic meningioma with late-phase accumulation on thallium-201 single-photon emission computed tomography: case report.

Authors:  Fumihiro Matano; Koji Adachi; Yasuo Murai; Takayuki Kitamura; Ryuji Ohashi; Akira Teramoto; Akio Morita
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-01-10       Impact factor: 1.742

3.  Grading meningioma: a comparative study of thallium-SPECT and FDG-PET.

Authors:  Sachi Okuchi; Tomohisa Okada; Akira Yamamoto; Mitsunori Kanagaki; Yasutaka Fushimi; Tsutomu Okada; Moritaka Yamauchi; Masako Kataoka; Yoshiki Arakawa; Jun C Takahashi; Sachiko Minamiguchi; Susumu Miyamoto; Kaori Togashi
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

4.  CyberKnife Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy As First-line Treatments for Imaging-diagnosed Intracranial Meningiomas.

Authors:  Yoshihiko Manabe; Taro Murai; Hiroyuki Ogino; Takeshi Tamura; Michio Iwabuchi; Yoshimasa Mori; Hiromitsu Iwata; Hirochika Suzuki; Yuta Shibamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-10-12       Impact factor: 1.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.